Summary
The purpose of this study is to understand if the drug Gleolan can improve the ability to show ovarian cancer tumor tissue and what is the benefit and risk of such during surgery and to understand the safety of the drug Gleolan in patients with ovarian tumors.
Description
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.
Principal Investigator
Stephen Bush
Study Coordinator
Lisa Luikart
Faculty Contact
Lisa Luikart - lisa.luikart@vandaliahealth.org
Research Contact
Lisa Luikart
CAMC Cancer Research Center
304.388.9944
Sex
Female
Age
18+
NCT Number
NCT05804370
IRB Number
25-1263
Phase(s)
3